![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Sunday, April 11, 2021 11:13:49 AM
The SAP and the endpoints the analyses will use when data is unblinded will be the revised reordered SAP and endpoints therewithin, ie, the primary endpoint is
"The primary objective of this study is to compare overall survival (OS) between patients randomized to DCVax-L and control patients from comparable, contemporaneous trials who received standard of care therapy only, in patients with newly diagnosed glioblastoma. This endpoint will be assessed using 3 different analyses"
and the first secondary endpoint is
"The first secondary objective is to compare overall survival (OS) between patients randomized to placebo who received DCVax-L treatment following disease recurrence and control patients from
comparable, contemporaneous clinical trials, in patients with recurrent GBM."
Source: https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001977-13/GB
As we all know, part of the reason for revising SAP (endpoints are part of it) is pseudo-progression wreaking havoc on "original" primary PFS endpoint and cross-over confoundment on "original" secondary endpoint OS."
Nonetheless, sponsors of trials may revise respective SAPs while they remain blinded according to FDA guideline, and it's exactly that NWBio revised its SAP while remained blinded. NWBio would be (has been) for the first time using this SAP to analyze unblinded data.
After all, since well more than five years have passed after the last patient in the trial was enrolled and treated, any data/analyses on PFS will be truly secondary, which may be used as an evidence support. The focus is now and should be now squarely on OS, in particular long-term survival.
It should be stressed NWBio revising SAP and endpoints are conducted to have more accurate and up-to-date metrics used to measure efficacy of the trial data, not to make up for "a failed trial" so it is not only necessary but essential.
One other reason for revising SAP is obviously as of today it is understood any immuno-therapeutic trials must be conducted longer enough to fully capture the effectiveness of the underlying immuno-therapeutic agents/vaccines due to normally delayed effects. For this reason, long-term OS is most important relative to the median OS, or the now obsolete surrogate endpoints such as PFS. Not only has NWBio exactly done that but it has acquired unprecedent rich and extensive data for all patients in the trial.
With Dr. Liau's presentation slides, particular those comparable, contemporaneous prior trial curves as well as the blinded data of Phase 3 DCVax-L trial as of 2017 (published in 2018) and its subsequent update data in 2018, plus the information arm data presented, it should be no difficult to conclude both the primary endpoint and the first secondary endpoint will be significant when analyses of unblinded data are announced in the near future.
GL
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM